Update on the use of memantine in Alzheimer’s disease

References

• GerzonKThe adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N`-adamantylureasJ Med Chem1963676076314184942
   PubMed Web of Science ®Google Scholar
• FleischhackerWWBuchgeherASchubertHMemantine in the treatment of senile dementia of the Alzheimer typeProg Neuropsychopharmacol Biol Psychiatry198610187933517967
   PubMed Web of Science ®Google Scholar
• WinbladBPoritisNMemantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)Int J Geriatr Psychiatry199914213514610885864
   PubMed Web of Science ®Google Scholar
• ReisbergBDoodyRStöfflerASchmittFFerrisSMöbiusHJMemantine Study GroupMemantine in moderate-to-severe Alzheimer’s diseaseN Engl J Med2003348141333134112672860
   PubMed Web of Science ®Google Scholar
• NICE technology appraisal guidance 111. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease (amended)National Institute for Health and Clinical ExcellenceLondon92007
   Google Scholar
• PaolettiPNeytonJNMDA receptor subunits: function and pharmacologyCurr Opin Pharmacol200771394717088105
   PubMed Web of Science ®Google Scholar
• ParsonsCGStöfflerADanyszWMemantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worseNeuropharmacology200753669972317904591
   PubMed Web of Science ®Google Scholar
• KaliaLVKaliaSKSalterMWNMDA receptors in clinical neurology: excitatory times aheadLancet Neurol20087874275518635022
   PubMed Web of Science ®Google Scholar
• ChohanMOIqbalKFrom tau to toxicity: emerging roles of NMDA receptor in Alzheimer’s diseaseJ Alzheimers Dis2006101818716988485
   PubMed Web of Science ®Google Scholar
• Degerman GunnarssonMKilanderLBasunHLannfeltLReduction of phosphorylated tau during memantine treatment of Alzheimer’s diseaseDement Geriatr Cogn Disord20072442475217700020
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyEuropean Public Assessment Report (EPAR)http://www.emea.europa.eu/humandocs/PDFs/EPAR/ebixa/160402en6.pdf
   Google Scholar
• Shua-HaimJSmithJPicardFSteady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by co-administration of memantine: an open-label, crossover, single-centre studyClin Drug Investig2008286361374
   PubMed Web of Science ®Google Scholar
• YaoCRaoufiniaAGoldMSteady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjectsJ Clin Pharmacol200545551952815831775
   PubMed Web of Science ®Google Scholar
• PericlouAPVenturaDShermanTRaoNAbramowitzWTLack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezilAnn Pharmacother200438913899415266045
   PubMed Web of Science ®Google Scholar
• PericlouAVenturaDRaoNAbramowitzWPharmacokinetic study of memantine in healthy and renally impaired subjectsClin Pharmacol Ther200679113414316413248
   PubMed Web of Science ®Google Scholar
• FreudenthalerSMeinekeISchreebKHBoakyeERemyUGGleiterCHInfluence of urine pH and urinary flow on the renal excretion of memantineBr J Clin Pharmacol1998465415469862242
   PubMed Web of Science ®Google Scholar
• WinbladBWimoAAlmkvistOOutcome measures in Alzheimer’s disease: do they go far enough?Dement Geriatr Cogn Disord200011suppl 131010971046
   PubMed Web of Science ®Google Scholar
• ReisbergBGlobal measures: utility in defining and measuring treatment response in dementiaInt Psychogeriatr200719342145617480241
   PubMed Web of Science ®Google Scholar
• SchmittFAAshfordWErnestoCThe severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s diseaseAlzheimer Dis Assoc Disord199711suppl 2S51S569236953
   PubMed Web of Science ®Google Scholar
• RosenWGMohsRCDavisKLA new rating scale for Alzheimer’s diseaseAm J Psychiatry198414111135613646496779
   PubMed Web of Science ®Google Scholar
• GalaskoDBennettDSanoMAn inventory to assess activities of daily living for clinical trials in Alzheimer’s diseaseAlzheimer Dis Assoc Disord199711suppl 2S33S399236950
   PubMed Web of Science ®Google Scholar
• van der KamPMolFWimmersMFHCBeoordelingsschaal voor oudere patienten (BOP)Deventer, The NetherlandsVan Loghum Slaterus1971
   Google Scholar
• CummingsJLMegaMGrayKRosenberg-ThompsonSCarusiDAGornbeinJThe Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementiaNeurology19944412230823147991117
   PubMed Web of Science ®Google Scholar
• van DyckCHTariotPNMeyersBMalca ResnickEthe Memantine MEM-MD-01 Study GroupA 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer diseaseAlzheimer Dis Assoc Disord200721213614317545739
   PubMed Web of Science ®Google Scholar
• TariotPNFarlowMRGrossbergGTGrahamSMMcDonaldSGergelIMemantine Study GroupMemantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trialJAMA2004291331732414734594
   PubMed Web of Science ®Google Scholar
• WimoAWinbladBStöfflerAWirthYMöbiusHJResource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s diseasePharmacoeconomics200321532734012627986
   PubMed Web of Science ®Google Scholar
• RiveBVercellettoMDamierFDCochranJFrançoisCMemantine enhances autonomy in moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry200419545846415156547
   PubMed Web of Science ®Google Scholar
• ReisbergBDoodyRStöfflerASchmittFFerrisSMöbiusHJA 24-week open-label extension study of memantine in moderate to severe Alzheimer diseaseArch Neurol2006631495416401736
   PubMedGoogle Scholar
• van DyckCHSchmittFAOlinJTMemantine MEM-MD-02 Study GroupA responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezilAm J Geriatr Psychiatry200614542843716670247
   PubMed Web of Science ®Google Scholar
• CummingsJLSchneiderETariotPNGrahamSMMemantine MEM-MD-02 Study GroupBehavioral effects of memantine in Alzheimer disease patients receiving donepezil treatmentNeurology2006671576316832078
   PubMed Web of Science ®Google Scholar
• SchmittFAvan DyckCHWichemsCHOlinJTthe Memantine MEM-MD-02 Study GroupCognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysisAlzheimer Dis Assoc Disord200620425526217132970
   PubMed Web of Science ®Google Scholar
• FeldmanHHSchmittFAOlinJTMemantine MEM-MD-02 Study GroupActivities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatmentAlzheimer Dis Assoc Disord200620426326817132971
   PubMed Web of Science ®Google Scholar
• PeskindERPotkinSGPomaraNMemantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trialAm J Geriatr Psychiatry200614870471516861375
   PubMed Web of Science ®Google Scholar
• PomaraNOttBRPeskindEResnickEMMemantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trialAlzheimer Dis Assoc Disord2007211606417334274
   PubMed Web of Science ®Google Scholar
• BakchineSLoftHMemantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month studyJ Alzheimers Dis20081319710718334761
   PubMed Web of Science ®Google Scholar
• PorsteinssonAPGrossbergGTMintzerJOlinJTMemantine MEM-MD-12 Study GroupMemantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trialCurr Alzheimer Res200851838918288936
   PubMed Web of Science ®Google Scholar
• McShaneRAreosa SastreAMinakaranNMemantine for dementiaCochrane Database Syst Rev20062CD00315416625572
   PubMedGoogle Scholar
• EmreMMecocciPStenderKPooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer’s diseaseJ Alzheimers Dis200814219319918560130
   PubMed Web of Science ®Google Scholar
• WinbladBJonesRWWirthYStöfflerAMöbiusHJMemantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trialsDement Geriatr Cogn Disord2007241202717496417
   PubMed Web of Science ®Google Scholar
• WilkinsonDAndersenHFAnalysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s diseaseDement Geriatr Cogn Disord200724213814517622761
   PubMed Web of Science ®Google Scholar
• DoodyRSTariotPNPfeifferEOlinJTGrahamSMMeta-analysis of six-month memantine trials in Alzheimer’s diseaseAlzheimers Dement20073171719595910
   PubMed Web of Science ®Google Scholar
• RainaPSantaguidaPIsmailaAEffectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guidelineAnn Intern Med2008148537939718316756
   PubMed Web of Science ®Google Scholar
• MaidmentIDFoxCGBoustaniMRodriguezJBrownRCKatonaCLEfficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysisAnn Pharmacother200842132818056833
   PubMed Web of Science ®Google Scholar
• WilcockGKBallardCGCooperJALoftHMemantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studiesJ Clin Psychiatry20086933413818294023
   PubMed Web of Science ®Google Scholar
• VidalJSLacombeJMDartiguesJFEvaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care databaseNeuroepidemiology200831319320018815451
   PubMed Web of Science ®Google Scholar
• WeyckerDTanejaCEdelsbergJCost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezilCurr Med Res Opin20072351187119717519086
   PubMed Web of Science ®Google Scholar
• GagnonMRiveBHuxMGuilhaumeCCost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in CanadaCan J Psychiatry200752851952617955915
   PubMed Web of Science ®Google Scholar
• FrançoisCSintonenHSulkavaRRiveBCost effectiveness of memantine in moderately severe to severe Alzheimer’s disease: a markov model in FinlandClin Drug Investig2004247373384
   Web of Science ®Google Scholar
• AntonanzasFRiveBBadenasJMGomez-LusSGuilhaumeCCost-effectiveness of memantine in community-based Alzheimer’s disease patients: An adaptation in SpainEur J Health Econ20067213714416670912
   PubMedGoogle Scholar
• KirbyJGreenCLovemanEA systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer’s diseaseDrugs Aging200623322724016608378
   PubMed Web of Science ®Google Scholar
• LovemanEGreenCKirbyJThe clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s diseaseHealth Technol Assess2006101iiiivixxi1160
   Web of Science ®Google Scholar
• JönssonLCost-effectiveness of memantine for moderate to severe Alzheimer’s disease in SwedenAm J Geriatr Pharmacother200532778616129384
   PubMedGoogle Scholar
• JonesRWMcCronePGuilhaumeCCost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspectiveDrugs Aging200421960762015260515
   PubMed Web of Science ®Google Scholar
• GeldmacherDSCost-effectiveness of drug therapies for Alzheimer’s disease: A brief reviewNeuropsychiatr Dis Treat20084354955518830441
   PubMedGoogle Scholar
• FeldmanHGauthierSHeckerJEconomic evaluation of donepezil in moderate to severe Alzheimer diseaseNeurology20046364465015326236
   PubMed Web of Science ®Google Scholar
• NeumannPJHealth utilities in Alzheimer’s disease and implications for cost-effectiveness analysisPharmacoeconomics200523437541
   Web of Science ®Google Scholar
• FarlowMRGrahamSMAlvaGMemantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trialsDrug Saf20083175778518558791
   PubMed Web of Science ®Google Scholar
• European Medicines AgencySummary of Product Characteristicshttp://www.emea.europa.eu/humandocs/PDFs/EPAR/ebixa/H-463-PI-en.pdf
   Google Scholar
• OttBRBlakeLMKaganEResnickMthe Memantine MEM-MD-11AB Study GroupOpen label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s diseaseJ Neurol2007254335135817345042
   PubMed Web of Science ®Google Scholar
• JonesRWBayerAInglisFBarkerAPhulRSafety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry200722325826217243195
   PubMed Web of Science ®Google Scholar
• AtriAShaughnessyLWLocascioJJGrowdonJHLong-term course and effectiveness of combination therapy in Alzheimer diseaseAlzheimer Dis Assoc Disord200822320922118580597
   PubMed Web of Science ®Google Scholar